# Aromasin (Exemestane) in Patients With Recurrent or Refractory Stage II - IV Epithelial Ovarian Cancer

> **NCT00261027** · PHASE2 · COMPLETED · sponsor: **Ottawa Hospital Research Institute** · enrollment: 30 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Exemestane

## Key facts

- **NCT ID:** NCT00261027
- **Lead sponsor:** Ottawa Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-01
- **Primary completion:** 2007-07
- **Final completion:** 2007-09
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2010-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00261027

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00261027, "Aromasin (Exemestane) in Patients With Recurrent or Refractory Stage II - IV Epithelial Ovarian Cancer". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT00261027. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*